Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680790 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07680790 · ClinicalTrials.gov record · last posted 2026-08-24

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

StatusNot Yet Recruiting
PhasePhase 3
Started2026-09-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

Protocol amendment history 2 changes detected by DataLookout

2026-08-25
Trial sites expanded: 200 → 208 locations
2026-07-16
Trial sites expanded: 180 → 200 locations
Trial Details
NCT Number NCT07680790
Lead Sponsor Bristol-Myers Squibb
Conditions Non-Small Cell Lung Cancer
Enrollment 850 participants
Start Date 2026-09-30
Primary Completion 2031-12-30 (estimated)
Study Completion 2031-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-24